Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.86 |
| ▸ | AXL | P30530 | 8/20 | 0.86 |
| ▸ | KDR | P35968 | 7/20 | 0.86 |
| ▸ | MERTK | Q12866 | 6/20 | 0.78 |
| ▸ | FLT3 | P36888 | 4/20 | 0.76 |
| ▸ | RET | P07949 | 3/20 | 0.76 |
| ▸ | KIT | P10721 | 3/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.71 |
| ▸ | FLT1 | P17948 | 3/20 | 0.71 |
| ▸ | AURKA | O14965 | 2/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.71 |
| ▸ | ABL1 | P00519 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096226 | 0.99 | MET (0.87) | METAXLKDRMERTKFLT3 | |
| SCHEMBL28438360 | 0.98 | MET (0.86) | METAXLKDRMERTKFLT3 | |
| SCHEMBL28434315 | 0.98 | MET (0.86) | METAXLKDRMERTKFLT3 | |
| Ammonia Solution, Strong SCHEMBL21273529 | 0.98 | MET (0.86) | METAXLKDRMERTKFLT3 | |
| Ammonia Solution, Strong SCHEMBL28439924 | 0.98 | MET (0.86) | METAXLKDRMERTKFLT3 | |
| SCHEMBL28442245 | 0.98 | MET (0.86) | METAXLKDRMERTKFLT3 | |
| SCHEMBL21273521 | 0.98 | MET (0.86) | METAXLKDRMERTKFLT3 | |
| SCHEMBL21273484 | 0.95 | MET (0.79) | METAXLKDRMERTKFLT3 | |
| SCHEMBL28441633 | 0.95 | MET (0.79) | METAXLKDRMERTKFLT3 | |
| SCHEMBL21291871 | 0.94 | MET (0.75) | METAXLKDRMERTKFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109496212-B | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition and application thereof | 北京康辰药业股份有限公司 | 2020-08-14 | — | — | CN | claimed |
| US-10723701-B2 | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2020-07-28 | — | — | US | claimed |
| EP-3530654-A1 | QUINOLINYL-SUBSTITUTED CARBOXYLIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2019-08-28 | — | — | EP | claimed |
| US-20190256470-A1 | QUINOLYL-SUBSTITUTED CARBOXYLIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION OF THE SAME, AND USE OF THE SAME | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2019-08-22 | — | — | US | claimed |
| CN-109496212-B | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition and application thereof | 北京康辰药业股份有限公司 | 2020-08-14 | — | — | CN | disclosed |
| US-10723701-B2 | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2020-07-28 | — | — | US | disclosed |
| EP-3530654-A1 | QUINOLINYL-SUBSTITUTED CARBOXYLIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723701-B2 | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same | AXL, JAK2, ABL1 | MET 129/4885AXL 1/4885KDR 21/4885 |
| US-20190256470-A1 | QUINOLYL-SUBSTITUTED CARBOXYLIC ACID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION OF THE SAME, AND USE OF THE SAME | AXL, JAK2, ABL1 | MET 130/4885AXL 1/4885KDR 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.